Last reviewed · How we verify
Mycamine (MICAFUNGIN)
Mycamine (Micafungin) is a small molecule echinocandin antifungal drug developed by Fujisawa Healthcare and currently owned by Teva Pharmaceuticals USA Inc. It targets the ATP-binding cassette sub-family G member 2, inhibiting the synthesis of beta-1,3-D-glucan, a critical component of fungal cell walls. Mycamine is approved to treat various candida infections, including peritonitis, septicemia, candidemia, esophageal candidiasis, and disseminated candidiasis. The drug has a half-life of 16 hours and is available as a generic medication. Mycamine is off-patent, with multiple generic manufacturers available.
At a glance
| Generic name | MICAFUNGIN |
|---|---|
| Sponsor | Teva Pharms Usa Inc |
| Drug class | Echinocandin Antifungal |
| Target | ATP-binding cassette sub-family G member 2 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2005 |
Approved indications
- Candida Peritonitis
- Candidal septicemia
- Candidemia
- Candidiasis of the esophagus
- Disseminated candidiasis
- Prevention of Disseminated Candidiasis
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Pyrexia
- Thrombocytopenia
- Neutropenia
- Headache
- Hypoglycemia
- Hyperkalemia
- Atrial Fibrillation
- Blood Alkaline Phosphatase Increased
Key clinical trials
- A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole (PHASE3)
- Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis (EPI Study) (PHASE4)
- Pharmacokinetics of Micafungin in Patients of Intensive Care Units (PHASE4)
- Fluconazole Versus Micafungin in Neonates With Candidiasis (PHASE2,PHASE3)
- Antibiotic Impregnated Beads in Osteomyelitis (PHASE4)
- A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia
- A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia (PHASE4)
- Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mycamine CI brief — competitive landscape report
- Mycamine updates RSS · CI watch RSS
- Teva Pharms Usa Inc portfolio CI